三个皮匠报告
最新
报告分类 研搜
BETA
政策库
自研报告
new
入驻
搜索
您的当前位置：首页 > 行业数据 > AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益
图片属性
图片格式：PNG 图片大小：898KB 图片尺寸：2304*1767
同报告图片
 / 4
AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益_第1页
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
AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益_第2页
fCDlk4HniYwgICAgICAgfCDljaDmr5QgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS18CnwgQkFJIFpFIEFOICB8IDM1JSAgfAp8IFRZVllUICAgICAgfCAyNSUgIHwKfCBBTCBSVUkgS0EgIHwgMTUlICB8CnwgS0VZVFJVREEgICB8IDEwJSAgfAp8IFRVTyBZSSAgICAgfCA1JSAgIHwKfCBIQU4gU0hJIFpIVUFORyB8IDMlICB8CnwgVEVDRU5UUklRICB8IDIlICAgfAp8IE9QRElWTyAgICAgfCAyJSAgIHwKfCBBTiBOSSBLRSAgIHwgMSUgICB8CnwgRU4gV0VJIERBICB8IDElICAgfAp8IE9USEVSUyAgICAgfCAxJSAgIHwKCui1hOaWmeadpea6kO+8mklRVklB77yM5Lit5rOw6K+B5Yi456CU56m25omA
AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益_第3页
AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益_第4页
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
AK104作为免疫疗法针对PD-L1低表达一线胃癌亦有优越的长期获益_第5页
所属报告： 康方生物-港股公司研究报告-双特异抗体龙头国际化之路现胜利曙光-240621（37页）.pdf
打包全文图表

相关数据

最新数据
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询商务合作事宜
copyright@2008-2013 长沙思想领动信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备2023027541号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠